Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell;Adulto Leukemia Groups
- Leiden
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- DOE - BASIC ENERGY SCIENCES
- OSTI ID:
- 1235456
- Journal Information:
- Leukemia, Vol. 19; ISSN 0887-6924
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
The feasibility of high-dose multiple daily fraction and its combination with anoxic cell sensitizers in the treatment of head and neck cancer: a pilot study of the radiotherapy group of the EORTC (European Organisation for Research on Treatment of Cancer)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Single-Fraction Carbon-Ion Radiation Therapy for Patients 80 Years of Age and Older With Stage I Non-Small Cell Lung Cancer
Journal Article
·
Fri Oct 01 00:00:00 EDT 1982
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:1235456
+4 more
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Journal Article
·
Tue Dec 01 00:00:00 EST 2015
· Lancet Oncology
·
OSTI ID:1235456
+41 more
Single-Fraction Carbon-Ion Radiation Therapy for Patients 80 Years of Age and Older With Stage I Non-Small Cell Lung Cancer
Journal Article
·
Sun May 01 00:00:00 EDT 2016
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:1235456
+6 more